Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

 Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

Shots:

  • The P-III COV-BARRIER study involves assessing Baricitinib (4mg, qd) + SoC (which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) vs PBO + SoC in 1525 patients in a ratio (1:1) hospitalized with COVID-19
  • The trial did not meet 1EPs i.e. progression to non-invasive ventilation or invasive mechanical ventilation including ECMO or death by Day 28 (17.5% vs 29.4%). The data showed a 38% reduction in mortality by Day 28
  • Lilly plans to publish the data in a peer-reviewed journal in the coming mos. and share the data with regulatory authorities in the US, EU, and other geographies

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: The Indian Express

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post